24/10/2011

Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy


Bitzer J. Kenemans P. Mueck A.O. FSDeducation Group (including Graziottin A.)
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy
Maturitas, 2008 Mar 20; 59 (3): 209-18

CONDIVIDI SU

Testosterone supplementation can be considered as a treatment option for surgically postmenopausal women with a distressful low sexual desire disorder, while on oestrogen therapy with or without progestagens. The purpose of this study is to review the available clinical data on the impact of exogenous testosterone containing postmenopausal hormone therapy on breast cancer risk.
No prospective randomized clinical trials were found. The five studies found (two case–control studies, two cohort studies and one retrospective observational study) showed inconsistent results. All studies had severe methodological limitations. Formulations and dosages used could be considered suboptimal.
At present, there are no valid randomized or observational clinical studies that provide evidence that the addition of testosterone to conventional postmenopausal hormone therapy influences breast cancer risk.

top


Available documents:
Full text of the article


By courtesy of Elsevier

FAIR USE: The content of this paper can be downloaded, printed and read for strictly personal and non-profit use. Any citation for didactic and/or scientific purpose must quote the title of the document, the name of the author(s), the data of the book or journal, and the URL of the site (www.alessandragraziottin.it).

WARNING: Every therapy must be discussed, tailored, prescribed and monitored by the M.D. personally consulted. Every information presented in this website can not surrogate the personal relationship with the caring physician nor be utilized without specific medical advice.